Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 36315X101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Madison Avenue Partners, LP
13G
|
5.5% |
6/23/2026
Event 6/15/2026
|
|
| Madison Avenue International LP | 5.5% | ||
| Madison Avenue Partners, LP | 5.5% | ||
| EMAI Management, LLC | 5.5% | ||
| Madison Avenue GP, LLC | 5.5% | ||
| Caraway Jackson Investments LLC | 5.5% | ||
| Eli Samaha | 5.5% | ||
|
Tang Capital Management LLC
13G
|
8.4% |
10/29/2025
Event 10/27/2025
|
|
| Tang Capital Management, LLC | 8.4% | ||
| Kevin Tang | 8.4% | ||
| Tang Capital Partners, LP | 5.0% | ||
| Tang Capital Partners International, LP | 3.4% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 3
|
13.2% |
7/28/2025
Event 7/24/2025
|
|
| EcoR1 Capital, LLC | 13.2% | ||
| Oleg Nodelman | 13.2% | ||
| EcoR1 Capital Fund Qualified, L.P. | 12.4% | ||
| EcoR1 Capital Fund, L.P. | 0.8% | ||
|
EcoR1 Capital, LLC
13D/A
Amendment 2
|
11.8% |
5/19/2025
Event 5/15/2025
|
|
| EcoR1 Capital, LLC | 11.8% | ||
| Oleg Nodelman | 11.8% | ||
| EcoR1 Capital Fund Qualified, L.P. | 11.1% | ||
| EcoR1 Capital Fund, L.P. | 0.7% | ||
|
Tang Capital Management LLC
13D
|
7.5% |
2/14/2025
Event 2/7/2025
|
|
| Tang Capital Management, LLC | 7.5% | ||
| Kevin Tang | 7.5% | ||
| Tang Capital Partners, LP | 4.2% | ||
| Tang Capital Partners International, LP | 3.0% | ||
| Tang Capital Partners III, Inc | 0.3% | ||
| Tang Capital Partners IV, Inc | 0% | ||
| Concentra Biosciences, LLC | 0% | ||
|
Gilead Sciences, Inc.
13D/A
Amendment 4
|
29.9% |
1/10/2025
Event 1/7/2025
|
|
| Gilead Sciences, Inc. | 29.9% | ||
| Gilead Therapeutics A1 Unlimited Company | 29.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 4.04 k | $120 k |
| 2026 Q2 | 77 | 32.1 M | $960 M |
| 2026 Q1 | 93 | 31.3 M | $938 M |
| 2025 Q4 | 93 | 31.4 M | $1.03 B |
| 2025 Q3 | 98 | 31.4 M | $1.09 B |
| 2025 Q2 | 99 | 31.9 M | $894 M |
| 2025 Q1 | 91 | 31.2 M | $783 M |
| 2024 Q4 | 90 | 31.1 M | $857 M |
| 2024 Q3 | 85 | 13.7 M | $393 M |
| 2024 Q2 | 91 | 20.1 M | $497 M |
| 2024 Q1 | 95 | 20.5 M | $661 M |
| 2023 Q4 | 102 | 20.0 M | $814 M |
| 2023 Q3 | 81 | 19.5 M | $674 M |
| 2023 Q2 | 83 | 19.7 M | $801 M |
| 2023 Q1 | 88 | 18.4 M | $713 M |
| 2022 Q4 | 84 | 13.2 M | $585 M |
| 2022 Q3 | 92 | 12.9 M | $551 M |
| 2022 Q2 | 90 | 12.9 M | $720 M |
| 2022 Q1 | 111 | 12.8 M | $796 M |
| 2021 Q4 | 108 | 10.9 M | $603 M |
| 2021 Q3 | 103 | 8.55 M | $450 M |
| 2021 Q2 | 127 | 7.51 M | $517 M |
| 2021 Q1 | 150 | 6.57 M | $506 M |
| 2020 Q4 | 130 | 4.59 M | $455 M |
| 2020 Q3 | 130 | 7.42 M | $1.05 B |
| 2020 Q2 | 154 | 7.63 M | $1.50 B |
| 2020 Q1 | 153 | 7.66 M | $1.50 B |
| 2019 Q4 | 153 | 7.57 M | $1.56 B |
| 2019 Q3 | 121 | 8.46 M | $1.29 B |
| 2019 Q2 | 126 | 8.67 M | $1.12 B |
| 2019 Q1 | 107 | 8.48 M | $998 M |
| 2018 Q4 | 93 | 8.14 M | $746 M |
| 2018 Q3 | 109 | 9.66 M | $1.09 B |
| 2018 Q2 | 88 | 7.64 M | $704 M |
| 2018 Q1 | 88 | 9.05 M | $903 M |
| 2017 Q4 | 83 | 9.94 M | $932 M |
| 2017 Q3 | 75 | 10.1 M | $1.03 B |
| 2017 Q2 | 83 | 12.1 M | $922 M |
| 2017 Q1 | 67 | 10.1 M | $872 M |
| 2016 Q4 | 55 | 10.1 M | $646 M |
| 2016 Q3 | 47 | 9.71 M | $628 M |
| 2016 Q2 | 38 | 9.79 M | $543 M |
| 2016 Q1 | 32 | 8.77 M | $367 M |
| 2015 Q4 | 44 | 8.24 M | $518 M |
| 2015 Q3 | 38 | 9.05 M | $368 M |
| 2015 Q2 | 41 | 8.81 M | $453 M |